GLRA2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL14047657	0.63	7/20
SCHEMBL8245345	0.56	7/20
SCHEMBL13702711	0.56	7/20
SCHEMBL13702712	0.56	7/20
SCHEMBL13702857	0.56	7/20
SCHEMBL8247069	0.55	7/20
Ginkgolide M (SCHEMBL13702682)	1.00	6/20
SCHEMBL13702707	0.65	6/20
SCHEMBL13702713	0.65	6/20
SCHEMBL13702823	0.65	6/20
SCHEMBL14539395	0.63	6/20
SCHEMBL14314424	0.62	6/20
SCHEMBL13702749	0.52	6/20
SCHEMBL8244980	0.68	5/20
SCHEMBL13702703	0.68	5/20
SCHEMBL13808827	0.68	5/20
SCHEMBL14539441	0.60	5/20
SCHEMBL8249829	0.55	5/20
SCHEMBL13702699	0.55	5/20
SCHEMBL8238605	0.54	5/20

Clinical trials — most relevant to GLRA2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effects of Levetiracetam on Alcohol Dependent Subjects	PHASE4	COMPLETED
Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine	PHASE4	COMPLETED
Postoperative Pain After Orthopedic Surgery: Does it Help to Give Fentanyl Before Start of Remifentanil Based Anesthesia?	PHASE3	COMPLETED
Effects of GABA-a-Agonists on Pain Mechanisms: An Experimental Study in Healthy Volunteers	PHASE3	COMPLETED
Memantine for Refractory OCD Patients	PHASE3	UNKNOWN
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD	PHASE3	COMPLETED
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia	PHASE2	COMPLETED
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders	PHASE2	COMPLETED
Therapeutic Efficacy of L-Ornithine L-Aspartate Infusion in Patients With Acute Liver Failure	PHASE2	UNKNOWN
Efficacy and Safety of Ramelteon Combined With Gabapentin in Treating Patients With Insomnia	PHASE2	COMPLETED
High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia	PHASE2	UNKNOWN
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia	PHASE1	COMPLETED
PET Imaging of Brain mGluR5 Receptors Using [18F]SP203	PHASE1	COMPLETED
A Single Ascending Dose Escalation to Investigate Safety and PK of VVZ-149 Injection in Healthy Older Male Volunteers	PHASE1	COMPLETED
Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast Cancer	PHASE1	WITHDRAWN
Brain Imaging, Genetics and Treatment for Major Depression	PHASE1	WITHDRAWN
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine	EARLY_PHASE1	COMPLETED
Changes in Glutamatergic Neurotransmission of Severe TBI Patients	EARLY_PHASE1	SUSPENDED
D-aspartate and Therapeutic Exercise	EARLY_PHASE1	UNKNOWN
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease	nan	COMPLETED
Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms	nan	COMPLETED
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia	nan	UNKNOWN
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation	nan	UNKNOWN
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX	nan	COMPLETED
An Assessment of Cognitive Function in Irritable Bowel Syndrome	nan	UNKNOWN
Oral Pregabalin Premedication for Postoperative Pain Relief	nan	UNKNOWN
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy)	nan	UNKNOWN
Brain Receptors in Sympathetic Nervous System Regulation	nan	COMPLETED
Metabotropic Receptors For Glutamate Type 3 In Parkinson's	nan	UNKNOWN
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a GLRA2 binder may also engage these)

Protein	Name	Similarity
GLRA3	Glycine receptor subunit alpha-3	1.000	landscape →
Q7TNC8	—	1.000	Q7TNC8 →
F1R8P4	—	1.000	F1R8P4 →
Q64018	—	1.000	Q64018 →
P57695	—	1.000	P57695 →
GLRA1	Glycine receptor subunit alpha-1	1.000	landscape →
P07727	—	1.000	P07727 →
P24524	—	1.000	P24524 →
P22771	—	1.000	P22771 →
O93430	—	0.999	O93430 →
Q61603	—	0.999	Q61603 →
Q91XP5	—	0.997	Q91XP5 →
Q17328	—	0.995	Q17328 →
Q94900	—	0.988	Q94900 →
P22933	—	0.987	P22933 →
P26714	—	0.987	P26714 →
P18506	—	0.987	P18506 →
G5EBR3	—	0.984	G5EBR3 →
GABRD	Gamma-aminobutyric acid receptor subunit delta	0.984	landscape →
P91730	—	0.982	P91730 →
P48168	—	0.982	P48168 →
O18276	—	0.981	O18276 →
P26153	—	0.981	P26153 →
GLRB	Glycine receptor subunit beta (Glycine recept	0.981	landscape →
A8WQK3	—	0.981	A8WQK3 →
GABRP	Gamma-aminobutyric acid receptor subunit pi (	0.980	landscape →
P20781	—	0.980	P20781 →
P02712	—	0.980	P02712 →
Q5EA06	—	0.980	Q5EA06 →
Q9GJS9	—	0.979	Q9GJS9 →